Short Interest in Design Therapeutics, Inc. (NASDAQ:DSGN) Increases By 8.1%

Posted by Donna Armstrong on Feb 4th, 2025

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 2,920,000 shares, an increase of 8.1% from the December 31st total of 2,700,000 shares. Currently, 9.3% of the company’s stock are sold short. Based on an average daily volume of 169,900 shares, the days-to-cover ratio is currently 17.2 days.

Institutional Investors Weigh In On Design Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in DSGN. Paloma Partners Management Co acquired a new stake in shares of Design Therapeutics during the third quarter worth $64,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Design Therapeutics during the 4th quarter valued at about $74,000. SG Americas Securities LLC acquired a new stake in Design Therapeutics during the third quarter worth about $66,000. The Manufacturers Life Insurance Company bought a new position in Design Therapeutics in the third quarter worth about $71,000. Finally, MetLife Investment Management LLC acquired a new position in Design Therapeutics in the third quarter valued at approximately $104,000. 56.64% of the stock is owned by institutional investors and hedge funds.

Design Therapeutics Stock Performance

Shares of NASDAQ:DSGN opened at $4.72 on Tuesday. The company has a fifty day simple moving average of $5.70 and a 200 day simple moving average of $5.36. Design Therapeutics has a 12-month low of $2.24 and a 12-month high of $7.77.

Design Therapeutics (NASDAQ:DSGN – Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.03. As a group, analysts expect that Design Therapeutics will post -0.91 earnings per share for the current fiscal year.

Design Therapeutics Company Profile

(Get Free Report)

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.